WCPO Cincinnati1m
FDA approves first new medication to treat schizophrenia in more than 30 years
People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...
Business Wire1h
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of ...
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
Monthly Prescribing Reference1h
Cobenfy Approved for Adult Patients with Schizophrenia
Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors.
New schizophrenia drug gets FDA approval, taking novel approach to treating brain disorder
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...
Dow Closes at Record High on Tame Inflation Report That Also Boosts Small Caps
(Reuters) -The blue-chip Dow Jones Industrial Average closed at a record high on Friday as investors welcomed a subdued ...
Boise State Public Radio2h
A new kind of drug for schizophrenia promises fewer side effects
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
BioWorld3h
US FDA clears Cobenfy, first new schizophrenia drug in decades
The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating ...
In a Victory for the Free Market, FDA Approves New Schizophrenia Drug
Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...
Bristol Myers Squibb stock rises following FDA approval of its schizophrenia drug
CNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy ...
devdiscourse3h
Bristol Myers' Breakthrough Schizophrenia Drug Secures FDA Approval
Bristol Myers Squibb has received U.S. FDA approval for a new schizophrenia drug, marking the first new antipsychotic medication in decades. The drug, Cobenfy, lacks warnings about increased mortality ...
FDA Approves First Novel Schizophrenia Drug in 70 Years, Impacting Up to 3 Million Patients in...
The FDA has approved Bristol Myers Squibb’s new schizophrenia drug, Cobenfy, the first novel treatment for schizophrenia in ...
Becker's Hospital Review4h
FDA approves schizophrenia treatment
The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to ...